首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

2103111

全球Charcot-Marie-Tooth症患者人數分析與預測（2026-2035 年）

Global Charcot-Marie-Tooth Disease Patient Population Analysis and Forecast, 2026 - 2035

出版日期: 2026年07月11日 | 出版商:

Knowledge Sourcing Intelligence | 英文 170 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

隨著遺傳診斷技術的進步、人們對遺傳性神經系統疾病認知的提高、新生兒和家庭篩檢範圍的擴大以及獲得專業神經科護理的機會改善，預計全球Charcot-Marie-Tooth(CMT) 患者人數將隨著疾病識別的進展而穩步成長。患者群體分析能夠全面揭示該疾病的盛行率、發病率、已確診和未確診人群、遺傳亞型分佈、人口趨勢、區域疾病負擔、醫療服務利用以及未來流行病學預測。隨著分子診斷技術的日益普及，醫療系統能夠識別出越來越多先前被誤診或長期未被確診的患者。

Charcot-Marie-Tooth，CMT）是最常見的遺傳性周邊神經病變之一，可影響所有年齡和種族的人群。此病以進行進行性肌無力、遠端肌肉萎縮、感覺障礙、足部畸形、步態異常和活動功能受損為特徵。疾病的嚴重程度因潛在的基因突變、發病年齡和疾病亞型而異。雖然CMT1仍然是全球最常見的亞型，但CMT2、CMT4、CMT4和其他罕見基因突變也佔患者總數的相當大一部分。

隨著次世代定序、全EXOME定序和綜合基因檢測技術的日益普及，診斷準確性不斷提高，疾病識別也得以更早進行。為患者家庭提供的遺傳諮詢、不斷擴大的患者登記庫以及多學科神經肌肉診療中心，都為更全面的流行病學監測提供了支持。這些進展正在加速臨床試驗的招募、精準醫學研究和疾病的長期監測，同時也有助於改善罕見神經系統疾病的醫療保健規劃。

對罕見疾病研究投入的增加、國際合作的拓展以及疾病修正治療的出現，預計將在預測期內進一步提高診斷率和患者參與度。隨著神經科醫生、基層醫療醫生和遺傳學家對罕見疾病的認知不斷提高，預計已開發醫療市場和新興醫療市場的確診患者人數將穩步成長。

市場促進因素

基因檢測的廣泛應用

次世代定序和綜合分子診斷方案顯著提高了診斷準確率。

早期發現致病突變導致確診患者數量增加，精準醫療的進步也促進了這一成長。

人們對罕見神經系統疾病的認知不斷提高

透過進行宣傳活動、培訓醫生、建立患者支持小組以及改善轉診途徑，可以促進遺傳性神經病變的早期發現。

人們意識的提高減少了診斷延誤，並改善了獲得專科醫療服務的機會。

病患登記系統的擴展

國內外的 CMT 登記處都在加強流行病學監測系統，並改善對患者的長期追蹤。

註冊數據支持醫療規劃、臨床研究和治療研究受試者的招募。

精準醫學的進展

分子層次表徵技術的進步使得根據特定基因突變對患者進行分類成為可能。

這將有助於制定個人化的治療策略和進行更準確的流行病學分析。

改善醫療基礎設施

專業神經肌肉疾病診所、遺傳諮詢服務和先進診斷檢測設施的擴展，正在改善已開發市場和新興市場獲得診斷的機會。

隨著醫療技術的現代化，預計未來診斷率將會提高。

市場限制因素

發展中地區缺乏診斷技術

在許多中低收入國家，基因檢測和專業神經科醫療服務資源有限是大量漏診的主要原因。

診斷延遲持續影響流行病學數據的準確性。

遺傳複雜性

導致這些疾病的基因突變數量龐大，使得診斷分類和患者分層變得極為複雜。

臨床症狀的多樣性會進一步延誤準確診斷。

缺乏流行病學數據

許多國家缺乏全面的國家遺傳性神經病變登記系統。

監測系統不足可能低估了全球疾病的實際負擔。

The global Charcot-Marie-Tooth (CMT) disease patient population is expected to grow steadily as advances in genetic diagnostics, increasing awareness of inherited neurological disorders, expanded newborn and family screening initiatives, and improved access to specialized neurological care enhance disease identification worldwide. Patient population analysis provides comprehensive insights into disease prevalence, incidence, diagnosed and undiagnosed patient pools, genetic subtype distribution, demographic trends, regional burden, healthcare utilization, and future epidemiological projections. As molecular diagnostic technologies become more widely available, healthcare systems are identifying increasing numbers of patients who were previously misdiagnosed or remained undiagnosed for extended periods.

Charcot-Marie-Tooth disease represents one of the most common inherited peripheral neuropathies, affecting individuals across all age groups and ethnic populations. The disorder is characterized by progressive muscle weakness, distal muscle atrophy, sensory impairment, foot deformities, gait abnormalities, and reduced functional mobility. Disease severity varies significantly depending on the underlying genetic mutation, age of onset, and disease subtype. CMT1 remains the most prevalent subtype globally, while CMT2, CMTX, CMT4, and other rare genetic variants contribute to the overall patient population.

Increasing adoption of next-generation sequencing, whole-exome sequencing, and comprehensive genetic testing panels is improving diagnostic accuracy and enabling earlier disease identification. Family-based genetic counseling, expanded patient registries, and multidisciplinary neuromuscular clinics are supporting more comprehensive epidemiological surveillance. These developments are also facilitating clinical trial recruitment, precision medicine research, and long-term disease monitoring while improving healthcare planning for rare neurological disorders.

Growing investment in rare disease research, expanding international collaborations, and the emergence of disease-modifying therapies are expected to further improve diagnosis rates and patient engagement throughout the forecast period. As awareness among neurologists, primary care physicians, and genetic specialists continues to increase, the diagnosed patient population is expected to expand steadily across both developed and emerging healthcare markets.

Market Drivers

Increasing Adoption of Genetic Testing

Next-generation sequencing and comprehensive molecular diagnostic panels are significantly improving diagnostic precision.

Earlier identification of disease-causing mutations is increasing the diagnosed patient population while supporting precision medicine initiatives.

Rising Awareness of Rare Neurological Disorders

Educational initiatives, physician training, patient advocacy organizations, and improved referral pathways are supporting earlier recognition of inherited neuropathies.

Growing awareness reduces diagnostic delays and improves access to specialized care.

Expansion of Patient Registries

National and international CMT registries are strengthening epidemiological surveillance and improving long-term patient tracking.

Registry data support healthcare planning, clinical research, and recruitment for therapeutic studies.

Growth in Precision Medicine

Improved molecular characterization enables classification of patients according to specific genetic mutations.

This supports individualized treatment strategies and more accurate epidemiological analysis.

Improving Healthcare Infrastructure

Expansion of neuromuscular specialty clinics, genetic counseling services, and advanced diagnostic laboratories is improving access to diagnosis in both developed and emerging markets.

Healthcare modernization is expected to increase future diagnosis rates.

Market Restraints

Underdiagnosis in Developing Regions

Limited access to genetic testing and specialist neurological services contributes to significant underdiagnosis in many low- and middle-income countries.

Delayed diagnosis continues to affect epidemiological accuracy.

Genetic Complexity

The large number of disease-causing genetic mutations complicates diagnostic classification and patient stratification.

Variation in clinical presentation may further delay accurate diagnosis.

Limited Epidemiological Data

Many countries lack comprehensive national registries for inherited neuropathies.

Incomplete surveillance systems may underestimate the true global disease burden.

Technology and Segment Insights

By Disease Subtype

CMT1 accounts for the largest proportion of diagnosed patients due to its relatively high prevalence among inherited demyelinating neuropathies.

CMT2, CMTX, CMT4, and rarer genetic variants continue to represent important patient segments requiring specialized diagnosis and management.

By Age Group

Although symptoms frequently begin during childhood or adolescence, diagnosis may occur at any age depending on disease severity and healthcare access.

Adult patients continue to represent the largest diagnosed population because of cumulative disease prevalence and delayed diagnosis.

By Diagnostic Method

Genetic testing has become the preferred diagnostic approach owing to its ability to accurately identify causative mutations.

Clinical neurological examination, nerve conduction studies, electromyography, family history assessment, and imaging continue supporting comprehensive diagnostic evaluation.

By Healthcare Setting

Specialized neuromuscular clinics and tertiary hospitals account for the majority of confirmed diagnoses because of access to advanced diagnostic technologies and multidisciplinary expertise.

Academic medical centers and genetic counseling services also play essential roles in patient identification and long-term follow-up.

Regional Insights

North America represents the largest diagnosed patient population due to widespread availability of genetic testing, advanced neuromuscular care, comprehensive patient registries, and strong awareness among healthcare professionals. The United States continues to lead epidemiological research and precision medicine initiatives for inherited neuropathies.

Europe maintains a substantial patient population supported by universal healthcare systems, specialized neurological centers, collaborative research networks, and well-established genetic diagnostic programs. Germany, the United Kingdom, France, Italy, Spain, and the Netherlands continue contributing significantly to epidemiological research and patient care.

Asia Pacific is expected to record the fastest growth in diagnosed patients during the forecast period owing to expanding healthcare infrastructure, increasing access to molecular diagnostics, rising awareness of inherited neurological disorders, and growing government investment in rare disease management across China, Japan, India, South Korea, and Australia.

Latin America and the Middle East & Africa are gradually improving patient identification through healthcare modernization, expanded access to genetic testing, and stronger collaboration with international neuromuscular research organizations.

Competitive and Strategic Outlook

The Charcot-Marie-Tooth disease patient population landscape is increasingly supported by collaboration among healthcare providers, pharmaceutical companies, biotechnology firms, genetic testing laboratories, patient advocacy organizations, and academic research institutions. Accurate epidemiological data are becoming increasingly important for clinical trial recruitment, healthcare resource allocation, reimbursement planning, and commercialization of emerging therapies.

Organizations continue investing in genetic screening technologies, digital patient registries, artificial intelligence-assisted diagnostics, and precision medicine platforms to improve patient identification and disease monitoring. Strategic collaborations between industry participants and healthcare systems are expected to strengthen epidemiological surveillance while supporting future therapeutic innovation.

Conclusion

The global Charcot-Marie-Tooth disease patient population is expected to increase steadily as advances in genetic diagnostics, expanding healthcare infrastructure, improved physician awareness, and growing access to specialized neurological care continue enhancing disease identification worldwide. Increasing adoption of molecular testing, stronger patient registries, supportive rare disease policies, and ongoing investment in precision medicine are expected to improve epidemiological accuracy and patient management throughout the forecast period. Although underdiagnosis, genetic complexity, and regional disparities remain important challenges, continued scientific and healthcare advancements are expected to strengthen long-term understanding of the global Charcot-Marie-Tooth disease burden.

Key Benefits of this Report

Insightful Analysis: Detailed epidemiological insights across regions, disease subtypes, age groups, diagnostic patterns, and patient demographics.
Strategic Planning Support: Understand patient distribution to optimize clinical development, commercialization, and market access strategies.
Market Drivers and Future Trends: Assess factors influencing diagnosis rates, prevalence, and future patient population growth.
Actionable Recommendations: Support investment, healthcare planning, and therapeutic development decisions.
Caters to a Wide Audience: Suitable for pharmaceutical companies, biotechnology firms, healthcare providers, research institutions, consultants, investors, and policymakers.

What Businesses Use Our Reports For

Patient population assessment, epidemiological forecasting, clinical trial planning, market opportunity evaluation, healthcare resource allocation, commercial strategy development, reimbursement planning, regulatory submissions, and competitive intelligence.

Report Coverage

Historical epidemiological data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Disease prevalence, incidence, diagnosed and undiagnosed patient population analysis
Patient segmentation by disease subtype, age group, gender, and geography
Regional epidemiology trends, healthcare access, diagnostic patterns, and future patient forecasts
Analysis of diagnosis rates, genetic testing adoption, unmet needs, and epidemiological growth opportunities

1. Executive Summary

1.1 Report Overview
- 1.1.1 Study Objectives
- 1.1.2 Scope of Patient Population Assessment
- 1.1.3 Key Epidemiological Findings
- 1.1.4 Forecast Assumptions (2025-2045)
1.2 Executive Insights
- 1.2.1 Global Disease Burden Overview
- 1.2.2 Diagnosed Population Trends
- 1.2.3 Genetic Testing Adoption Trends
- 1.2.4 Patient Identification Challenges
- 1.2.5 Future Epidemiological Outlook
1.3 Key Conclusions
- 1.3.1 High-Burden Patient Segments
- 1.3.2 Growth Drivers of Diagnosed Population
- 1.3.3 Regional Patient Distribution Trends
- 1.3.4 Strategic Implications for Stakeholders

2. Patient Population Overview

2.1 Disease Background
- 2.1.1 Definition and Classification
- 2.1.2 Genetic Basis of Disease
- 2.1.3 Clinical Manifestations
- 2.1.4 Disease Progression Patterns
2.2 Epidemiology Overview
- 2.2.1 Global Prevalence Overview
- 2.2.2 Global Incidence Overview
- 2.2.3 Diagnosed Population Overview
- 2.2.4 Undiagnosed Population Assessment
2.3 Historical Epidemiology Trends
- 2.3.1 Historical Prevalence Trends
- 2.3.2 Historical Incidence Trends
- 2.3.3 Historical Diagnosis Trends
- 2.3.4 Impact of Genetic Testing Expansion
2.4 Forecasted Patient Population Trends (2025-2045)
- 2.4.1 Total Prevalent Cases Forecast
- 2.4.2 Incident Cases Forecast
- 2.4.3 Diagnosed Population Forecast
- 2.4.4 Treated Population Forecast

3. Disease Burden and Unmet Need Analysis

3.1 Clinical Burden Assessment
- 3.1.1 Neurological Impairment Burden
- 3.1.2 Functional Disability Burden
- 3.1.3 Quality-of-Life Impact
- 3.1.4 Caregiver Burden Assessment
3.2 Economic Burden Assessment
- 3.2.1 Direct Healthcare Costs
- 3.2.2 Indirect Economic Costs
- 3.2.3 Productivity Loss Impact
- 3.2.4 Long-Term Disability Burden
3.3 Diagnostic Burden Analysis
- 3.3.1 Diagnostic Delays
- 3.3.2 Misdiagnosis Challenges
- 3.3.3 Access to Genetic Testing
- 3.3.4 Referral Pathway Challenges
3.4 Unmet Need Assessment
- 3.4.1 Disease-Modifying Therapy Gap
- 3.4.2 Access to Specialized Care
- 3.4.3 Early Diagnosis Gaps
- 3.4.4 Regional Healthcare Inequalities

4. Mechanism and Modality Landscape

4.1 Mechanism of Action Landscape
- 4.1.1 PMP22 Gene Regulation Approaches
  - 4.1.1.1 Scientific Basis
  - 4.1.1.2 Target Population Relevance
  - 4.1.1.3 Epidemiological Impact Potential
- 4.1.2 Gene Replacement Therapies
  - 4.1.2.1 Mechanistic Overview
  - 4.1.2.2 Eligible Patient Population
  - 4.1.2.3 Future Adoption Potential
- 4.1.3 RNA-Based Therapeutics
  - 4.1.3.1 Antisense Technologies
  - 4.1.3.2 RNA Interference Approaches
  - 4.1.3.3 Target Population Analysis
- 4.1.4 Neuroprotective Therapies
- 4.1.5 Regenerative Therapies
- 4.1.6 Symptom-Modifying Approaches
4.2 Mechanism Clustering Analysis
- 4.2.1 Asset Distribution by MoA
- 4.2.2 Targeted Patient Segments
- 4.2.3 First-in-Class Innovation Analysis
- 4.2.4 Best-in-Class Potential Analysis
4.3 Modality Analysis
- 4.3.1 Small Molecules
- 4.3.2 Biologics
- 4.3.3 RNA Therapies
- 4.3.4 Gene Therapies
- 4.3.5 Cell-Based Therapies

5. Clinical Development Intelligence

5.1 Clinical Trial Landscape
- 5.1.1 Active Clinical Trials
- 5.1.2 Recruiting Studies
- 5.1.3 Completed Studies
- 5.1.4 Terminated Studies
- 5.1.5 Historical Development Trends
5.2 Trial Design Benchmarking
- 5.2.1 Study Design Trends
- 5.2.2 Sample Size Benchmarking
- 5.2.3 Endpoint Analysis
- 5.2.4 Trial Duration Benchmarking
5.3 Patient Recruitment Intelligence
- 5.3.1 Recruitment Challenges
- 5.3.2 Recruitment Timelines
- 5.3.3 Geographic Recruitment Distribution
- 5.3.4 Impact of Rare Disease Status
5.4 Clinical Success Benchmarking
- 5.4.1 Historical Success Rates
- 5.4.2 Failure Pattern Analysis
- 5.4.3 Dropout Trend Analysis
- 5.4.4 Regulatory Success Factors

6. Patient Population Segmentation Analysis

6.1 Patient Population by Disease Type
- 6.1.1 Charcot-Marie-Tooth Type 1
  - 6.1.1.1 Prevalent Cases
  - 6.1.1.2 Incident Cases
  - 6.1.1.3 Diagnosed Population
  - 6.1.1.4 Forecast Analysis (2025-2045)
- 6.1.2 Charcot-Marie-Tooth Type 2
  - 6.1.2.1 Prevalent Cases
  - 6.1.2.2 Incident Cases
  - 6.1.2.3 Diagnosed Population
  - 6.1.2.4 Forecast Analysis (2025-2045)
- 6.1.3 Charcot-Marie-Tooth Type 4
  - 6.1.3.1 Prevalent Cases
  - 6.1.3.2 Incident Cases
  - 6.1.3.3 Diagnosed Population
  - 6.1.3.4 Forecast Analysis (2025-2045)
- 6.1.4 X-Linked Charcot-Marie-Tooth Disease
  - 6.1.4.1 Prevalent Cases
  - 6.1.4.2 Incident Cases
  - 6.1.4.3 Diagnosed Population
  - 6.1.4.4 Forecast Analysis (2025-2045)
6.2 Patient Population by Age Group
- 6.2.1 Pediatric Population
  - 6.2.1.1 Prevalence Assessment
  - 6.2.1.2 Diagnosis Trends
  - 6.2.1.3 Forecast Outlook
- 6.2.2 Adolescent Population
  - 6.2.2.1 Prevalence Assessment
  - 6.2.2.2 Diagnosis Trends
  - 6.2.2.3 Forecast Outlook
- 6.2.3 Adult Population
  - 6.2.3.1 Prevalence Assessment
  - 6.2.3.2 Diagnosis Trends
  - 6.2.3.3 Forecast Outlook
- 6.2.4 Elderly Population
  - 6.2.4.1 Prevalence Assessment
  - 6.2.4.2 Diagnosis Trends
  - 6.2.4.3 Forecast Outlook
6.3 Patient Population by Diagnosis Status
- 6.3.1 Diagnosed Population
  - 6.3.1.1 Current Cases
  - 6.3.1.2 Forecast Trends
- 6.3.2 Undiagnosed Population
  - 6.3.2.1 Hidden Disease Burden
  - 6.3.2.2 Diagnostic Gap Analysis
- 6.3.3 Misdiagnosed Population
  - 6.3.3.1 Misclassification Trends
  - 6.3.3.2 Impact on Epidemiology
- 6.3.4 Genetically Confirmed Population
  - 6.3.4.1 Genetic Testing Penetration
  - 6.3.4.2 Future Diagnostic Trends

7. Probability of Success and Risk Analysis

7.1 Phase Transition Probability Assessment
- 7.1.1 Preclinical to Phase I
- 7.1.2 Phase I to Phase II
- 7.1.3 Phase II to Phase III
- 7.1.4 Phase III to Approval
7.2 Risk-Adjusted Patient Access Assessment
- 7.2.1 Eligible Population by Development Stage
- 7.2.2 Future Treated Population Scenarios
- 7.2.3 Access Risk Assessment
- 7.2.4 Attrition Impact on Patient Access
7.3 Development Risk Analysis
- 7.3.1 Scientific Risks
- 7.3.2 Clinical Risks
- 7.3.3 Regulatory Risks
- 7.3.4 Commercial Access Risks

8. Launch Timeline and Commercial Potential

8.1 Regulatory Approval Forecasts
- 8.1.1 Near-Term Launch Candidates
- 8.1.2 Mid-Term Launch Candidates
- 8.1.3 Long-Term Development Programs
8.2 Patient Adoption Forecasts
- 8.2.1 Eligible Population Assessment
- 8.2.2 Uptake Scenario Analysis
- 8.2.3 Geographic Adoption Differences
8.3 Future Treated Population Forecast
- 8.3.1 Treated Patient Growth
- 8.3.2 Therapy Penetration Trends
- 8.3.3 Impact on Disease Burden

9. Competitive Pipeline Landscape

9.1 Competitive Benchmarking
- 9.1.1 Company Ranking Framework
- 9.1.2 Innovation Leadership Analysis
- 9.1.3 Asset Concentration Analysis
9.2 Company-Wise Pipeline Assessment
- 9.2.1 Leading Developers
- 9.2.2 Emerging Innovators
- 9.2.3 Academic and Nonprofit Contributors
9.3 Asset-Level Intelligence Profiles
- 9.3.1 Molecule Overview
- 9.3.2 Developer Assessment
- 9.3.3 Mechanism of Action
- 9.3.4 Clinical Phase
- 9.3.5 Target Patient Population
- 9.3.6 Competitive Positioning
9.4 Leader versus Challenger Analysis
- 9.4.1 Innovation Matrix
- 9.4.2 Development Readiness
- 9.4.3 Future Competitive Outlook

10. Geographic Analysis

10.1 North America
- 10.1.1 Clinical Trial Activity
- 10.1.2 Regulatory Environment
- 10.1.3 Innovation Hubs
- 10.1.4 Patient Population Trends
10.2 Europe
- 10.2.1 Clinical Trial Activity
- 10.2.2 Regulatory Environment
- 10.2.3 Innovation Hubs
- 10.2.4 Patient Population Trends
10.3 Asia-Pacific
- 10.3.1 Clinical Trial Activity
- 10.3.2 Regulatory Environment
- 10.3.3 Innovation Hubs
- 10.3.4 Patient Population Trends
10.4 Latin America
- 10.4.1 Clinical Trial Activity
- 10.4.2 Regulatory Environment
- 10.4.3 Innovation Hubs
- 10.4.4 Patient Population Trends
10.5 Middle East & Africa
- 10.5.1 Clinical Trial Activity
- 10.5.2 Regulatory Environment
- 10.5.3 Innovation Hubs
- 10.5.4 Patient Population Trends

11. Key Countries Analysis

11.1 United States
11.2 Canada
11.3 Germany
11.4 United Kingdom
11.5 France
11.6 Italy
11.7 Spain
11.8 China
11.9 Japan
11.10 India
11.11 South Korea
11.12 Australia
11.13 Brazil
11.14 Mexico
11.15 Saudi Arabia
11.16 South Africa

Standard Country Framework

Clinical Trial Activity

Regulatory Timelines

Key Sponsors

Patient Population Trends

Diagnosis Rate Assessment

Future Epidemiological Outlook

12. Deals and Investment Landscape

12.1 Licensing Agreements
- 12.1.1 Asset Licensing Trends
- 12.1.2 Platform Licensing Agreements
12.2 Co-Development Partnerships
- 12.2.1 Industry Collaborations
- 12.2.2 Academic Partnerships
12.3 Mergers and Acquisitions
- 12.3.1 Asset Acquisitions
- 12.3.2 Strategic Transactions
12.4 Funding Landscape
- 12.4.1 Venture Capital Funding
- 12.4.2 Public Financing
- 12.4.3 Grant and Foundation Funding
12.5 Investment Outlook
- 12.5.1 Investment by Modality
- 12.5.2 Investment by Development Stage
- 12.5.3 Future Capital Flow Trends

13. Future Outlook and Strategic Insights

13.1 Future Epidemiology Outlook
- 13.1.1 Global Patient Growth Trends
- 13.1.2 Diagnostic Expansion Impact
- 13.1.3 Genetic Testing Adoption Effects
13.2 Future Treatment Access Outlook
- 13.2.1 Emerging Therapy Impact
- 13.2.2 Patient Identification Improvements
- 13.2.3 Access Expansion Scenarios
13.3 Strategic Recommendations
- 13.3.1 Opportunities for Developers
- 13.3.2 Opportunities for Healthcare Systems
- 13.3.3 Opportunities for Patient Advocacy Organizations

14. Methodology and Data Framework

14.1 Research Methodology
- 14.1.1 Primary Sources
- 14.1.2 Secondary Sources
- 14.1.3 Data Validation Methods
14.2 Epidemiology Methodology
- 14.2.1 Prevalence Estimation Framework
- 14.2.2 Incidence Estimation Framework
- 14.2.3 Diagnosis Rate Modeling
- 14.2.4 Forecasting Methodology
14.3 Pipeline Verification Framework
- 14.3.1 ClinicalTrials.gov Validation
- 14.3.2 EU Clinical Trials Register Validation
- 14.3.3 Company Pipeline Validation
- 14.3.4 Regulatory Filing Verification
14.4 Probability Modeling Framework
- 14.4.1 Success Probability Assumptions
- 14.4.2 Risk Adjustment Methodology
- 14.4.3 Scenario Development Framework
14.5 Appendix
- 14.5.1 Epidemiology Definitions
- 14.5.2 Disease Classification Framework
- 14.5.3 Clinical Trial Database
- 14.5.4 Country-Level Data Tables
- 14.5.5 Abbreviations and Acronyms
- 14.5.6 Source Validation Log